| Name | Title | Contact Details |
|---|
EYEVANCE Pharmaceuticals` mission is to develop and commercialize INNOVATIVE and IMPACTFUL ophthalmic products to enable optimal vision and better quality of life for all patients
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Advanced Targeting Systems is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Linical is a leading CRO conducting clinical trials in oncology, infectious disease, and CNS. Let us support your journey, the right way. Learn more here!
3129 Sanofi SA is a French multinational healthcare company headquartered in Paris, France.